ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine.

@article{Greenberg2008ACAM2000AN,
  title={ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine.},
  author={Richard N. Greenberg and Jeffrey S. Kennedy},
  journal={Expert opinion on investigational drugs},
  year={2008},
  volume={17 4},
  pages={555-64}
}
BACKGROUND Due to concern over i) expiration of currently available calf-lymph vaccine (Dryvax); ii) calf lymph as a vaccine (bovine spongiform encephalopathy [BSE], other possible contaminations and animal welfare); and iii) use of variola as a weapon for bioterrorism, a new and safer vaccinia-based smallpox vaccine derived from new cell culture-based technology was proposed. Federally funded work by Acambis, Inc. resulted in FDA approval for ACAM2000 in August 2007. OBJECTIVES This paper… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…